T HE NUCLEAR HORMONE receptors (NRs) are ligand-dependent transcription factors that profoundly participate in multiple aspects of development, differentiation and homeostasis in eukaryotes (1) (2) (3) . NRs bind to the specific cis-DNA sequences, so-called hormone response elements in the vicinity of the promoter of target genes, and stimulate gene transcription in a ligand-dependent manner (4, 5) . NRs possess a characteristic modular structure conserved through the large superfamily of NRs that consists of the DNA-binding domain (DBD), ligand-binding domain (LBD), hinge region between DBD and LBD, and two separate transcription activation domains termed N-terminal activation function-1 (AF-1) and C-terminal AF-2 (1-3). NRs have recently been shown to function in concert with basal transcription factors and multiple transcriptional cofactors including corepressors and coactivators (6) (7) (8) (9) . Different portions of NRs directly interact with these distinct coregulators in ligand-dependent and independent manners (6) (7) (8) (9) . In the case of TR and RAR, ligand binding causes a conformation change in the LBD allowing release of corepressors from the hinge region and recruitment of coactivator complexes to the AF-2 domain (10) (11) (12) (13) (14) (15) . The coactivators themselves and their associated cofactors possess histone acetyltransferase activity, and targeted hyperacetylation of core histones by these factors has been postulated to be a key step responsible for hormone-dependent gene activation by NRs (16) (17) (18) .
The DBD of NRs appears to be mainly involved in DNA binding and receptor dimerization (5) . Recent cumulating evidence indicates that this domain also serves as a direct interaction interface for a variety of cellular factors including a tumor suppressor, an oncoprotein, transcription factors, an RNA-binding protein, viral proteins, and an enzyme involved in a signal transduction pathway (19) (20) (21) (22) (23) (24) (25) (26) . In some cases, NRs appear to interfere with the function of these DBD-binding factors independent of DNA binding (19, (22) (23) (24) . Direct evidence that the DBD-binding factor of NRs is involved in ligand-dependent transactivation has been shown by Cheng et al. (27) who reported that the hematopoietic bZIP protein, p45/NF-E2 interacts with the DBD of TR and RAR and potentiates liganddependent gene activation in cooperation with the cAMP response element-binding protein-binding protein (CBP) . A novel protein termed SNURF (small nuclear ring finger protein), which was cloned using the DBD of AR as bait, can potentiate gene activation mediated by AR, GR, and PR in a ligand-dependent manner, possibly by functioning as a bridging factor between these NRs and the TATA-binding protein, a basal transcription factor (28) . A cold-inducible coactivator of NRs, PGC-1, binds to the DBD and a part of the hinge region of PPAR ␥ (29). The p300/CBP associated factor has a histone acetylase activity and directly binds to the DBD of NRs to function as a coactivator (30) . Paradoxically, histone deacetylases, HDAC1 and HDAC2, have also been found to bind the DBD of TR and might participate in the negative regulation of the TSH ␤ subunit gene by thyroid hormone (31) . These findings suggest that the DBD-interacting proteins might be classified as a novel class of coregulators involved in transcriptional control by NRs.
To gain additional insights into the role of DBD-binding factors of NRs for ligand-dependent transactivation, we cloned a protein that binds to the DBD of human TR␤1 using the yeast two-hybrid system. The nucleotide sequence of the cloned cDNA was found to be identical to the human immunodeficiency virus type 1 (HIV-1) Tat binding protein-1 (TBP-1) that was originally isolated as a protein interacting with the HIV-1 Tat transactivator (32) . TBP-1 potentiated the TR-mediated, but not other NR-mediated, transactivations in mammalian cells. Although TBP-1 itself possessed an intrinsic transactivation function, augmentation of TR-mediated transactivation by TBP-1 required the intact AF-2 of TR. TBP-1 directly interacted with the TR-interacting protein 1 (Trip1), a putative transcriptional mediator for TR that binds to the AF-2 of TR in a ligand-dependent manner (33, 34) . These findings demonstrated that TBP-1 interacts not only with Tat but also with TR, and TBP-1 might function as a novel DBD-binding coactivator specifically involved in the TR-mediated gene activation.
RESULTS

Cloning of a Protein That Interacts with the DBD of TR␤1
To isolate the proteins that interact with the DBD of TR, we performed a yeast two-hybrid screen of a Hela cell cDNA library using the DBD plus a part of the hinge region of human TR␤1 as bait (Fig. 1A) . Sixteen positive clones were obtained, and their partial nucleotide sequences were determined. A clone containing the identical partial cDNA sequence was also isolated from a human lung cDNA library. A computer search for data resources suggested that the partial cDNA sequence isolated from two different libraries was apparently identical to that of the human TBP-1 that was previously cloned as a protein interacting with the HIV-1 Tat transactivator (32) . TBP-1 has been reported to be predominantly localized in the nucleus (32) . The reported TBP-1 was encoded by 404 amino acids and was shown to possess a putative nucleotide binding motif and an RNA/DNA helicase motif in the C-terminal conserved ATPase domain (CAD), a characteristic structure of an ATPase family (Fig. 1B) (32, 35) . It was also noted that a heptad repeat of hydrophobic amino acids, reminiscent of a leucine zipper, was located in the N-terminal region of TBP-1 (Fig. 1B) (32) . A putative NR-box motif (L-X-X-L-L), an NR-binding site identified in several coactivator proteins (36), was not found in TBP-1. Importantly, TBP-1 shares significant homology with Trip1/mouse SUG1 (mSUG1) and MB67-interacting protein (MIP) 224, other members of (Fig. 1C) (34, 37, 38) . Further sequence analyses of the cDNA clone isolated in our yeast dual-hybrid screen revealed that the cDNA contained the full-open reading frame of the originally isolated TBP-1 (32). Ohana et al. reported the cloning of a longer version of TBP-1 cDNA that has two additional in-frame ATG codons 35 and 19 amino acids upstream of the first ATG in the originally isolated TBP-1 (39) . The present clone lacked the sequence corresponding to the first in-frame 16 amino acids of the longer version of TBP-1. The third ATG codon was previously established to be used as an initiation codon (32) . Therefore, the third and probably the second ATG codon might be used in our cloned TBP-1 cDNA when translated in vitro. For convenience, numbering of the amino acids of TBP-1 in this manuscript followed that of the longer TBP-1 cDNA version (39)
TBP-1 Interacts with the DBD but Not with the LBD of TR
To confirm the interaction between TBP-1 and TR, TRDBD plus a part of the hinge region (TRD-H) ligated to GAL4DBD (pGBT9TRD-H) and the full-length TBP-1 ligated to GAL4AD (pGAD10TBP-1) were cotransformed into yeast containing the lacZ reporter gene under control of the GAL4-binding site, and the protein-protein interaction was analyzed by a ␤-galactosidase assay. To determine whether TBP-1 also binds to a domain other than TRDBD, the interaction of TBP-1 with GAL4DBD separately fused to the DBD alone (pGBT9TRDBD), and the remainder of the hinge region plus LBD (pGBT9TRLBD) of TR␤1 was tested. As shown in Fig. 2 , TBP-1 interacted with TRDBD and TRD-H, but not with TRLBD. GAL4DBD itself (pGBT9) did not interact with TBP-1 ( Fig. 2A) , and GAL4TRDBD did not show any ␤-galactosidase activity in the presence of GAL4AD alone (data not shown), indicating specificity of the interaction. TRLBD did not interact with TBP-1 even in the presence of T 3 ( Fig. 2A) , whereas the interaction of TRLBD with Trip1 fused to GAL4AD was T 3 -dependent in our yeast system in agreement with a previous study (34) (data not shown). To next examine whether TBP-1 physically associates with TR in mammalian cells, CV-1 cells were cotransfected with TR and FLAG-tagged TBP-1 expression vectors. Protein complexes associated with TBP-1 were first immunoprecipitated with the anti-FLAG monoclonal antibody, and the bound proteins were subsequently analyzed by immunoblotting with an anti-TR-specific antibody. As shown in Fig. 2B , TR protein was detected in immunoprecipitates from cells transfected with both TBP-1 and TR expression vectors, but not with the empty FLAG vector and TR expression plasmid, confirming that TR and TBP-1 are found as complexes in vivo.
Glutathione-S-Transferase (GST) Interaction Assay
We next assessed the in vitro interaction of TBP-1 with TR using a GST pull-down assay. [ , and the full-length TR␤1 were synthesized using in vitro transcription/translation and were incubated with a GST fused full-length TBP-1 (GST-TBP-1) immobilized to glutathione beads. After extensive washing, TRA/B-DBD, TRA/B-hinge, and the full-length TR were retained by GST-TBP-1, but not by GST itself (Fig.  3A) . In contrast, TRA/B and TRLBD did not bind to GST- A, Interactions of TR␤1 polypeptides fused to GAL4DBD (pGBT9TR) with the full-length TBP-1 ligated to GAL4AD (pGAD10TBP-1) in yeast were measured by ␤-galactosidase (␤-gal) activity. The interaction between pGBT9TRLBD and pGAD10TBP-1 was measured in the absence and presence of 100 nM T 3 . B, Nuclear extracts from CV-1 cells transfected with pKCR2TR␤1 (7.5 g/dish) in the presence of a vector encoding FLAG-tagged TBP-1 or an empty FLAG vector (7.5 g/dish) were immunoprecipitated by M2 anti-FLAG monoclonal antibody. The protein complexes were resolved by SDS-PAGE and transferred to nitrocellulose membranes. Immunoblotting was performed using an anti-TR␤1 monoclonal antibody. An arrow indicates the TR␤1 protein, and an asterisk indicates a nonspecific binding.
TBP-1. The interaction of the full-length TR with TBP-1 was not T 3 dependent as expected from the findings obtained in the yeast experiment. The binding of TR to GST-TBP-1 was comparable to that of a GST-fused receptor interaction domain of the nuclear receptor corepressor (N-CoR) (Fig. 3B ). These findings confirmed the interaction of TBP-1 with the DBD of TR in vitro.
Mapping the TR-Interacting Domain in TBP-1
To localize the domain necessary for interaction with TR in TBP-1, GST-fusion proteins of the N-terminal (residues 17-176) and C-terminal portions (residues 176-439) of TBP-1 were synthesized, and their interaction with [ 35 S]-labeled full-length TR␤1 was examined using a GST pull-down assay. As shown in Fig. 4A , TR bound to the N-terminal portion of TBP-1 as well as to the fulllength TBP-1. In contrast, no apparent TR binding to the C-terminal portion of TBP-1 was observed. T 3 again did not affect the interaction between TR and TBP-1. The interaction of the N-terminal region, but not the C-terminal portion, of TBP-1 with TR was also confirmed using the yeast two hybrid-system (Fig. 4B ). These findings indicated that the N-terminal portion of TBP-1 containing a leucine zipper-like structure serves as the interaction interface for TRDBD.
TBP-1 Potentiated the Ligand-Dependent Transactivation by TR␤1 in Mammalian Cells
We next analyzed whether TBP-1 affects the liganddependent transactivation function of the TR in mammalian cells using a transient transfection assay. In TRdeficient CV-1 cells, the activity of promoter carrying the palindromic thyroid hormone response element (TRE) was stimulated by the cotransfected hTR␤1 in the pres- ence of 10 nM of T 3 . The cotransfection of TBP-1 augmented the ligand-dependent stimulation of the promoter activity by TR in a dose-dependent manner (Fig.  5A) . A similar ligand-dependent augmentation by TBP-1 was observed with a reporter construct carrying another TRE, DR4, that is direct repeat-type TRE with a spacer of four nucleotides (Fig. 5B) . In contrast, TBP-1 did not potentiate the activities of thymidine kinase (TK), Simian virus 40 early and Rous sarcoma virus (RSV) long terminal repeat (LTR) promoters that lack the positive TRE in the presence of liganded TR (data not shown). The transcriptional enhancement by TBP-1 of the palindromic TRE was not observed when a TR with a mutation in the first zinc finger motif in DBD (C127S) was cotransfected (Fig. 5C) . Moreover, TBP-1 lacking the N-terminal leucine zipper-like structure did not potentiate transcription in the presence of wild-type TR in transient transfection assays (Fig. 5D ). These findings collectively suggest that TBP-1 potentiated the ligand-dependent transactivation of TR in mammalian cells, and that TBP-1 functioned in concert with TR that bound to DNA.
TBP-1 Selectively Enhances the TR-Mediated Transactivation
TR is known to be encoded by two different genes, c-erb A ␣ and ␤ (40, 41). To clarify whether TBP-1 functions in a TR isoform-specific manner, hTR␣1 was cotransfected with TBP-1 into CV-1 cells in the presence of the palindromic TRE reporter gene. TBP-1 could potentiate transactivation by TR␣1 in the presence of T 3 similar to TR␤1 (Fig. 6A) . Identical findings were obtained using the DR4 reporter gene (data not shown). We next examined whether TBP-1 can potentiate transactivation by other members of NRs in CV-1 cells. As shown in Fig. 6B , the cotransfected TBP-1 did not significantly enhance activation of the promoters containing cognate hormone response elements by RAR, RXR, PPAR␥, and ER in the presence of individual specific ligands. The direct interaction of TBP-1 with RXR and RAR, known heterodimer partners for TR (5, 42) , was also evaluated using the yeast two-hybrid system. As shown in Fig. 6C , TBP-1 interacted neither with the full-length RXR in the absence and presence of 9-cis-retinoic acid (9-cis-RA) nor the DBD plus the hinge region of RAR. Moreover, [
35 S]-labeled full-length RAR, RXR, PPAR, and ER did not bind to GST-TBP-1 in in vitro pull-down assays (Fig.  6D ). These findings indicated that TBP-1 selectively potentiates the transactivation function of TR.
TBP-1 Possesses an Autonomous Activation Function
To investigate whether TBP-1 possesses an intrinsic activation function, the N-terminal and C-terminal portions of TBP-1 were ligated to GAL4DBD and cotransfected with the upstream activating sequence (UAS)-TK reporter gene into CV-1 cells. As shown in Fig. 7 , GAL4VP16 significantly activated the UAS-TK promoter activity. GAL4TBP-1N did not stimulate the promoter activity over that of GAL4DBD itself. In contrast, GAL4TBP-1C significantly stimulated the promoter activity. Identical findings were obtained using Hela cells (data not shown). These findings indicated that TBP-1 might possess an intrinsic activation function in the Cterminal CAD region.
Mutation of the Potential ATP-Binding Motif in the CAD Abolished Augmentation of the TRMediated Transcriptional Activation by TBP-1
Ohana et al. (39) reported that mutation or deletion of the putative ATP-binding motif and helicase motif in -1N ), C-terminal (GST TBP-1C), and full-length TBP (GST TBP-1) were analyzed using a pull-down assay in the presence or absence of 100 nM T 3 . B, Interactions of the TRDBD plus a part of the hinge region fused to GAL4DBD (pGBT9TR) or GAL4DBD alone (pGBT9) with TBP-1 polypeptides expressed from pGAD10TBP-1, TBP-1N, and TBP-1C were measured by ␤-gal assay in the yeast two-hybrid system. the CAD region abolished the intrinsic activation potential of TBP-1. We, therefore, evaluated whether these motifs in the CAD are necessary for enhancement of the TR-mediated transactivation by TBP-1 using a transient transfection assay. As shown in Fig.  8A , a mutation introduced into the putative ATP-binding site (K233H) abolished augmentation of the palindromic reporter activity. In contrast, TBP-1 with a mutation within the putative helicase motif (D286A) showed significant enhancement similar to the wildtype TBP-1. These mutant TBP-1s were similarly bound to TR in a GST pull-down assay (Fig. 8B) . These findings clearly revealed that the potential nucleotide binding motif, but not the helicase motif in CAD, was required for augmentation by TBP-1 of the TR-mediated gene activation. A, pKCR2TR␤1 (83 ng/well) was cotransfected into CV-1 cells with the palindromic TRE reporter gene (PAL) (1.7 g/well) in the absence or presence of increasing amounts of pKCR2TBP-1 (170, 500, and 830 ng/well). Luciferase activity was measured after 48 h incubation with or without 10 nM T 3 . Values represent the mean Ϯ SE from triplicate determinants. B, pKCR2TR␤1 (83 ng/l) was cotransfected with the DR4 TRE reporter gene (1.7 g/well) in the presence of pKCR2 or pKCR2TBP-1 (830 ng/well). C, The wild-type or a mutant TR␤1 possessing a substitutive mutation in DBD (C127S) (83 ng/well) was cotransfected with PAL (1.7 g/well) in the absence or presence of pKCR2TBP-1 (830 ng/well). D, The wild-type or mutant TBP-1 lacking the N-terminal leucine zipper-like structure (830 ng/well) was cotransfected with PAL (1.7 g/well) in the presence of pKCR2TR␤1 (83 ng/well). 
TBP-1 Requires the AF-2 Domain of TR for Transcriptional Enhancement
In addition to its intrinsic activation potential, it was unclear whether TBP-1 requires interaction with other transcriptional regulators to augment ligand-dependent transactivation by TR. To assess this possibility, we first examined whether TBP-1 could enhance the transactivation function of an AF-2 mutant TR (E457A). E457A has been shown to bind to TRE and possesses an affinity for T 3 similar to the wild-type receptor, but lacks the ligand-dependent transactivation function because of its impaired ability for interacting with coactivators (43) . As shown in Fig. 9 , TBP-1 did not potentiate the promoter activity carrying the palindromic TRE in the presence of liganded E457A, although TBP-1 could directly bind to E457A in a pulldown assay. This indicated that the potentiation by TBP-1 of transactivation by TR might be dependent on the AF-2 domain of TR.
TBP-1 and Coactivators Synergistically Stimulate TR-Mediated Transactivation
The AF-2 of TR has recently been demonstrated to directly interact with multiple protein complexes containing the coactivators and cointegrators (6-9). We, therefore, examined whether TBP-1 influences the enhancement of TR-mediated transactivation by coactivators using a transient transfection assay. As shown in Fig. 10A , cotransfection of three coactivators of TR, steroid receptor coactivator 1 (SRC-1), p120, and CBP enhanced the ligand-dependent stimulation by TR of the palindromic TRE in a magnitude similar to the cotransfected TBP-1. When TBP-1 was simultaneously transfected with these coactivators, the promoter activity in the presence of liganded TR was strongly augmented (Fig. 10A) . We next examined whether TBP-1 can directly interact with these coactivators using the in vitro pull-down assay. As shown in Fig. 10B , GST-TBP-1 did not interact with in vitro translated SRC-1, p120, and CBP. These findings suggest that TBP-1 could synergistically function with the AF-2-interacting coactivators in the absence of direct interaction.
TBP-1 Directly Interacts with Trip1 in Vivo and in Vitro
TBP-1 has been shown to be able to form a homodimer with TBP-1 itself and to weakly form a heterodimer with TBP7, a putative ATPase highly homologous to MIP224 (38) , possibly through its N-terminal leucine zipper-like motif (39) . These findings suggested that the homo-or heterodimer formation of TBP-1 might be important for its function and led us to evaluate the interaction between TBP-1 and Trip1, a The N-terminal (residues 7-176) or C-terminal portion (residues 176-439) of TBP-1 ligated to GAL4DBD or GAL4DBD alone (830 ng/well) was cotransfected with the UAS-TK reporter gene (1.7 g/well) into CV-1 cells. GAL4VP16 (83 ng/well) was used as a positive control. Luciferase activity was measured as described in Materials and Methods. member of the ATPase family that binds to the AF-2 of TR in a ligand-dependent manner (34) . As shown in Fig. 11A, [ 35 S]-labeled Trip1 bound to GST-TBP-1, but not to GST itself. Moreover, Trip1 interacted with the N-terminal, but not the C-terminal, region of TBP-1 (Fig. 11A) . Synthesis of TBP-1 proteins of appropriate molecular weights were confirmed by SDS-PAGE analyses (Fig. 11B ). In agreement with the previous findings (39), [ 35 S]-labeled TBP-1, in addition to Trip1, bound to GST-TBP-1 in a pull-down assay (data not shown). The interaction of the N-terminal, but not the C-terminal, region of TBP-1 with Trip1 was also confirmed using the yeast two-hybrid system (Fig. 11C) . We next examined the effect of transfection of Trip1 on TR-mediated transcription in the presence of cotransfected TBP-1 using a transient transfection into CV-1 cells. Transfection of Trip1 did not enhance the palindromic TRE-driven promoter activity in the presence of cotransfected TR in agreement with previous findings (34, 37) . In contrast, cotransfection of both TBP-1 and Trip1 further augmented the promoter activity in the presence of T 3 when compared with that in the presence of TBP-1 alone (Fig. 11D) . These in vitro and in vivo findings suggest that TBP-1 binding to the DBD of TR might cooperate with Trip1, which interacts with the AF-2 via a protein-protein interaction.
Overexpression of TBP-1 Did Not Alter TR Protein Levels
TBP-1 has previously been identified as a component of the 19S regulatory subunit of the 26S proteasome that degrades ubiquitinated proteins (35, 44, 45) . Recent studies demonstrated that several NRs including ER, vitamin D receptor (VDR), and promyelocytic leukemia-RAR fusion protein were degraded via the proteasome system (46-48). It was, therefore, anticipated that overexpression of the single component of the proteasome complex in transient transfection assays might disrupt the normal processing function of the protein degradation system, thereby increasing the available TR proteins, resulting in potentiation of the promoter activity. To clarify whether levels of the TR protein are affected by overexpression of TBP-1, we quantitated the TR␤1 protein levels in the absence or presence of cotransfected TBP-1 using Western blot analysis. As shown in Fig. 12 , the cellular levels of TR␤1 protein were not altered in the absence or presence of TBP-1 transfected in conditions identical to that used in transient transfection experiments. These findings suggest that TBP-1 might not potentiate the TR-mediated gene activation by increasing TR protein levels.
DISCUSSION
TBP-1 was originally isolated as a protein interacting with the HIV-1 Tat transactivator and was reported to inhibit the TAT-mediated activation of the HIV-1 LTR promoter (32) . Proteins highly homologous to the human TBP-1 have subsequently been cloned from different species indicating that TBP-1 might have some evolutionary conserved functions (49) (50) (51) (52) . The TBP-1 gene is mapped to human chromosome 11p (53, 54) and is ubiquitously expressed in a variety of human cell lines and in rodent tissues (32, 55, 56) . However, the physiological importance of TBP-1 in the regulation of the transcription of specific cellular genes remains to be elucidated. The present study, therefore, provides the first evidence that TBP-1 is involved in transcriptional activation of the thyroid hormoneresponsive gene. TBP-1 belongs to a protein family possessing the CAD named AAA family (ATPases associated with a variety of cellular activities) (35) , and the CAD region in TBP-1 shares significant homology with those of Trip1, mSUG1, and other members of the ATPase family (34, 35, 37) . When compared with Trip1/mSUG1, several unique features of TBP-1 as a transcriptional cofactor for TR were observed in the present study. First, TBP-1 constitutively bound to TR in the presence and absence of T 3 , whereas Trip1/mSUG1 binds to the receptors in a ligand-dependent manner (34, 37) . Second, TBP-1 interacted with the DBD of TR, whereas Trip1/mSUG1 interacts with the LBD of TR (34, 37) . Third, overexpression of TBP-1 strongly potentiated the ligand-dependent transactivation by TR in mammalian cells. In contrast, cotransfected Trip1 did not enhance the TR-mediated transactivation in transient transfection assays (Fig. 11D and Ref. 34) . Lastly, TBP-1 appeared to selectively function with TR, whereas Trip1/mSUG1 has been shown to interact not only with TR, but also with RAR, RXR, VDR, and ER (34, 37, 57).
In addition, TBP-1 has a characteristic function that requires the AF-2 domain of TR to potentiate the TRmediated transcription. The AF-2 of NRs was recently shown to interact with multiprotein complexes containing coactivators and cointegrators in the presence of ligand (6) (7) (8) (9) . In the present study, we showed that TBP-1 was able to directly interact and synergistically function with Trip1, one of the AF-2 interacting cofactors that bind to TR in a ligand-dependent manner. Moreover, the present transfection study revealed that TBP-1 could synergistically enhance the TR-mediated transactivation with a subset of coactivators such as SRC-1, p120, and CBP that interact with the AF-2 of TR, although TBP-1 did not interact with these coactivators in vitro. These findings collectively suggest that TBP-1 might function in cooperation with other transcriptional cofactors interacting with the AF-2 of TR, such as Trip1, to augment the ligand-dependent gene activation.
In agreement with a previous finding reported by Ohana et al. (39) , we could detect an intrinsic activation function of TBP-1 using a mammalian one-hybrid assay and showed that the activation domain resided within the C-terminal CAD region. TBP-1 lacked the consensus L-x-x-L-L sequence, a characteristic NRbinding site in many coactivators that possess intrinsic histone acetyltransferase activity (36) . Mutation of the potential ATP-binding motif, but not the helicase motif, abolished the enhancement of TR-mediated transactivation by TBP-1 in the present study. The recombinant rat SUG1 has been established to possess an RNA-dependent ATPase activity (58) . Moreover, mSUG1 has been shown to have a bona fide helicase activity (59) and interacts with the p89/XPB (xeroderma pigmentosum B) subunit of TFIIH (60) . The DEAD (the predicted ATPase B motif)-box proteins such as the eukaryotic translation initiation factor 4A and p68 exhibit an RNA-unwinding activity as well as RNAstimulated ATPase activity (60, 61). Endoh et al. (62) recently reported that p68 stimulates the ER-mediated gene activation via a protein-protein interaction with the AF-1 of ER and showed that the intrinsic helicase activity was dispensable for the coactivator function of p68. In conjunction with these findings, the present study indicates that the putative ATPase activity of TBP-1 is responsible for enhancement of the liganddependent gene activation by TR.
TBP-1 and Trip1/mSUG1 are the integral components of the 19S regulatory subunit of the 26S proteasome that degrades the ubiquitinated and nonubiquitinated proteins contributing to a variety of cellular regulatory processes (35, 44, 45) . It was, therefore, anticipated that ectopic expression of TBP-1 might alter the levels of TR␤1 protein, thereby affecting the ]-labeled full-length Trip1 were examined using a pull-down assay. B, SDS-PAGE analysis of the GST-fused TBP-1 proteins used in panel A. C, Interactions of the N-terminal and C-terminal portions of TBP-1 in pGBT9 with pGAD10Trip1 and pGAD10 were examined using the yeast two-hybrid system. ␤-gal assay was performed as describe above. D, Increasing amounts of pKCR2TBP-1 (170, 500, and 830 ng/well) were transfected with pKCR2TR␤1 (17 ng/well) into CV-1 cells in the absence or presence of pKCR2Trip1 (170 ng/well). Luciferase activities of PAL in the absence or presence of T 3 were measured and were expressed as light units/g protein.
TR-mediated transactivation. However, TBP-1 selectively enhanced the TR-mediated, but not other NRmediated, activation in the present transfection studies. Moreover, TBP-1 overexpressed in a condition identical to that used in transfection studies did not alter the steady-state levels of TR␤1 protein. Makino et al. recently reported that the complex of proteasomal ATPases could directly interact with the TATA-binding protein, and that TBP-1 was present in the complex as well as mSUG1, SUG2, TBP7, MSS1, S4, and a novel transcription regulatory factor, TIP (TBP-interacting protein)120 (63) . These findings taken together suggest that the proteasomal function of TBP-1 was likely to be dispensable for augmentation of the TR-mediated gene transcription. TBP-1, like other proteasomal ATPases, might be a multifunctional protein directly involved in the regulation of gene transcription as well as in protein degradation.
The HIV-1 Tat is a powerful activator of viral gene expression from the integrated LTR (64) . TR has previously been demonstrated to directly interact with Tat through its DBD and has been shown to stimulate activity of the HIV-1 LTR promoter in the presence of T 3 (22) . HIV-1 Tat has recently been shown to directly recruit the histone acetyltransferases p300/CBP and p300/CBP associated factor to the viral RNA (65) . These findings suggested that the Tat/liganded TR complex on the HIV-1 LTR promoter might facilitate recruitment of the host transcriptional coregulators to activate the viral gene expression in vivo. As mentioned above, TBP-1 inhibits activation of the Tat-mediated HIV-1 LTR promoter in vivo (32) . Taken together with the present findings, TBP-1 might compete for binding of Tat to the DBD of TR, thereby, in part, suppressing the Tat-mediated activation of the HIV-1 promoter. Further studies are required to ascertain this possibility.
MATERIALS AND METHODS
Plasmids
Expression vectors for human (h)TR␤1, TR␣1, RAR␣, RXR␣, PPAR␥, and ER in a pKCR2 expression vector were described previously (43, (66) (67) (68) . Two mutant TRs (C127S and E457A) in pKCR2 were described previously (43) . Firefly luciferase reporter plasmids (pA3Luc) carrying the palindromic or DR4 TRE were previously described (43) . Luciferase reporter vectors containing the direct repeat-type (DR5) retinoic acid response element or direct repeat-type (DR1) retinoid X response element/peroxisome proliferator-activated response element upstream of the TK gene promoter were described previously (43, 68) . A reporter plasmid carrying the estrogen response element was previously described (43) . pA3Luc driven by the TK gene promoter (TK109) and RSV long terminal repeat (RSV400) were described previously (67, 69) . The Simian virus 40 early promoter was excised from pGL3-promoter vector (Promega Corp., Madison, WI) using HindIII and SmaI and inserted into the HindIII/SmaI cloning site in the promoter-less pSV0Luc (69) . An expression vector for TBP-1 was constructed by ligating the cloned TBP-1 cDNA into pKCR2 (pKCR2TBP-1). Mutant TBP-1 expression vectors (K233H and D286A) (39) were created using a sequential PCR method as described previously (70) . A mutant TBP-1 cDNA that lacked the N-terminal leucine zipper-like structure (residues 69-439) was amplified by PCR and subcloned into the pKCR2 expression vector (pKCR2delta N-TBP-1). Expression vectors for SRC-1, p120, Trip1, and CBP in pKCR2 were described previously (43) . The cDNA fragments encoding A/B domain (residues 1-106), A/B domain plus DBD (residues 1-180), and from A/B domain to a part of the hinge region (residues 1-205) of TR␤1 were amplified by PCR using the peA101 plasmid (40) as the template and ligated into pKCR2GAL4DBD (43) to create pKCR2TRA/B, A/B-DBD, and A/B-hinge, respectively. The PCR-amplified cDNA fragment encoding DBD (residues 106-180) of TR␤1 was inserted into pGAD10 (CLONTECH Laboratories, Inc., Palo Alto, CA) (pGAD10TRDBD). A cDNA fragment encompassing a part of the hinge and LBD of TR␤1 (residues 204 to 461) was amplified by PCR and inserted to pKCR2 (pKCR2TRLBD) and pGAD10 (pGAD10TRLBD). pGBT9TBP-1, pGBT9TBP-1N, and pGBT9TBP-1C were constructed by inserting the full-length and the PCR-amplified N-terminal (residues 17-176) and C-terminal (residues 176-439) portions of TBP-1 cDNA, respectively, into pGBT9 (CLONTECH Laboratories, Inc.). pGBT9RARDBD and pGBT9RXR were constructed by ligating a PCR-amplified cDNA fragment encoding the DBD plus a part of the hinge region of hRAR␣ (residues 85-175) and the full-length hRXR␣ into pGBT9. pGAD10TBP-1 and pGAD10Trip1 were created by ligating the full-length TBP-1 and Trip1 cDNA (43) , respectively, into pGAD10.
Yeast Two-Hybrid System
A yeast two-hybrid screen of Hela cell and human lung MATCHMAKER cDNA libraries (CLONTECH Laboratories, Inc.) was performed to identify the clones that interacted with TRDBD. A cDNA fragment encoding the DBD and a part of the hinge region of hTR␤1 (residues 106-205) was amplified by PCR, ligated in-frame into the EcoRI site of pGBT9, and used as bait. The library, with randomly primed size-selected cDNA fragments in pGAD10, used the GAL4 activation domain (GAL4AD) as a transcriptional activator. The yeast strain HF7c (MATa, ura3-52, his3-200, lys2-801, ade2-101, trp1-901, leu2-3, 112, gal4-542, gal80-538, LYS2 : : GAL1-HIS3, URA3 : : (GAL4 17-mers)3-CYC1-LacZ) was used for cotransformation. Transformants were plated onto synthetic complete media plates lacking histidine, leucine, and tryptophan. Approximately 1 ϫ 10 6 transformants were screened for interaction with TRDBD. After 3-4 d, viable colonies were dissolved in 40 l of Z buffer (0.06 M Na 2 HPO 4 , 0.04 M NaH 2 PO 4 , 1 mM MgSO 4 , 10 mM KCl). After two rounds of freezing and thawing, ␤-galactosidase activity was measured by a chemiluminescent assay (Tropix, Bedford, MA). Identification of positive clones was performed by culturing Hisϩ, LacZϩ transformant yeast colonies in 3 ml of liquid synthetic Cells CV-1 cells in 100-mm 2 dishes were transfected with pKCR2TR␤1 (5 g/dish) and TBP-1 (10 g/dish) using a calcium phosphate precipitation method, and nuclear extracts were prepared after incubation for 48 h with 10 nM T 3 or vehicle alone. Forty micrograms of nuclear proteins were resolved by SDS-PAGE, transferred to a nitrocellulose membrane, and blotted with an anti-TR␤1 monoclonal antibody. Levels of T␤1 protein were visualized as described in Materials and Methods. media (Trpϩ, Leu). Isolation of yeast DNA was performed as described previously (43) . The resulting plasmid DNA was transformed by electroporation into HB101 Escherichia coli containing a leuB mutation to allow for selection of the pGAD10 plasmid.
Sequence Analysis
The plasmids isolated from positive colonies were amplified on a large scale, and the nucleotide sequences of both strands were determined using an autosequencer (PRISMTM 310, PE Applied Biosystems, Tokyo, Japan). All the PCRamplified cDNA fragments used for plasmid construction were verified by direct sequencing.
GST Pull-Down Assay
[ 35 S] methionine-labeled full-length and partial proteins of hTR␤1 were synthesized by in vitro transcription/translation from pKCR2TRA/B, TRA/B-DBD, TRA/B-hinge, TRLBD, and the full-length TR using T7 RNA polymerase and a TNTcoupled reticulocyte lysate system (Promega Corp.). [ 35 S]-labeled full-length RAR, RXR, PPAR␥, and ER proteins were synthesized in vitro from the pKCR2 expression vectors. Synthesis of proteins of expected molecular weights was confirmed by SDS-PAGE analyses. The full-length and PCRamplified partial fragments of TBP-1 cDNA were ligated in-frame into pGEX4T1 (Pharmacia Biotech, Piscataway, NJ) to yield GST fusion proteins in E. coli DH5␣. A cDNA fragment encoding the receptor interaction domain of N-CoR was amplified by PCR using pKCR2N-CoRI (43) as a template and subcloned in flame into pGEX4T1. The GST fusion proteins were purified on glutathione-agarose beads (Sigma, St. Louis, MO) and analyzed by SDS-PAGE. Interaction assays and autoradiographies were performed as described previously (43) . Bound protein was quantified by Molecular Imager FX (Bio-Rad Laboratories, Inc., Hercules, CA).
Cell Culture, Transfection, and Luciferase Assay CV-1 and Hela cells were grown in DMEM supplemented with 10% FBS, as described previously (67, 68) . Twenty-four hours before transfection, cells were split into six-well plates in subconfluency. Transient transfection was performed using a calcium phosphate precipitation method, as described previously (67, 68) . The total amounts of transfected plasmids were adjusted by adding an empty expression vector in all experiments. Luciferase assay was performed and the luciferase activity was normalized by the protein concentration, as described previously (67, 68) . All the transfection experiments were repeated at least twice with triplicate determinants. T 3 , all-trans-RA, 9-cis-RA, and E2 were purchased from Sigma. Troglitazone was from Sankyo Co., Ltd. (Tokyo, Japan).
Immunoprecipitation and Immunoblotting
The full-length TBP-1 cDNA was ligated in flame into a pFLAG-CMV-2 expression vector (Sigma) and transfected into CV-1 cells cultured in 100 mm 2 dishes in the presence of pKCR2TR␤1 using a calcium phosphate precipitation method. Forty-eight hours after transfection, nuclear extracts were prepared as previously described (70) . After immunoprecipitation with an anti-FLAG M2 monoclonal antibody (Sigma), the samples were resolved on 10% polyacrylamide gels under denaturing conditions and transferred onto nitrocellulose membranes (Hybond ECL, Amersham Pharmacia Biotech, Arlington Heights, IL). After incubation in a blocking buffer [20 mM Tris-HCl (pH 7.6), 137 mM NaCl and 5% skimmed milk] for 1 h at room temperature, the membranes were incubated overnight at 4 C with an anti-TR antibody (J52), which recognizes the human TR␤1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). After extensive washing, the membranes were incubated with a sheep antimouse Ig antibody, and TR proteins were visualized with the ECL Plus Western blotting detection kit (Amersham Pharmacia Biotech).
Mammalian One-Hybrid Assay
The cDNAs corresponding to the N-terminal (residues 17-176) and C-terminal portions (residues 176-439) of TBP-1 were amplified by PCR, ligated in frame into the EcoRI site of pMGAL4DBD (CLONTECH Laboratories, Inc.), and transfected with UAS-TK luciferase reporter (43) into CV-1 and Hela cells as described above. The herpes simplex virus VP16 ligated to GAL4DBD (GAL4VP16) (CLONTECH Laboratories, Inc.) was used as a positive control. Luciferase activities were measured as described above.
Statistical Analysis
Statistical analyses were performed using Duncan's multiple range test among multiple groups. The level of significance was set at P Ͻ 0.05.
